Shares of Cadeler A/S – ADR (NYSE:CDLR) rose sharply in pre-market trading after the company reported interim financial results for the first half of 2026.

Revenue for the first six months of 2026 jumped to EUR 408 million from EUR 188 million in the year-ago period. Profit for the period climbed 54% to EUR 88 million.

Cadeler also maintained its full-year 2026 revenue guidance in the range of EUR 854 to 944 million.

Cadeler shares jumped 6% to $25.40 in pre-market trading.

Here are some other stocks moving in pre-market trading.

Gainers

• CID HoldCo Inc (NASDAQ:DAIC) gained 94.7% to $3.37 in pre-market trading after jumping 306% on Monday. DAIC is a distressed microcap facing Nasdaq delisting and loan-default risks, according to company filings made last week.
• Xiao-I Corp (NASDAQ:AIXI) rose 89.7% to $0.87 in pre-market trading. Xiao-I, last week, announced it will change its ADS ratio from 1‑to‑60 to 1‑to‑420 ordinary shares and disclosed it received a non‑compliance notice from Nasdaq.
• Autonomix Medical Inc (NASDAQ:AMIX) rose 67.2% to $8.98 in pre-market trading after the company announced a $4.9 million warrant inducement.
• 707 Cayman Holdings Ltd (NASDAQ:JEM) rose 51.8% to $5.80 in pre-market trading after dipping over 6% on Monday.
• Biodexa Pharmaceuticals PLC-ADR (NASDAQ:BDRX) gained 34% to $1.61 in pre-market trading after declining over 5% on Monday.
• BTC Digital Ltd (NASDAQ:BTCT) gained 19.6% to $2.08 in pre-market trading. BTC Digital shares jumped over 52% on Monday after the company announced that construction of its cryptocurrency computing infrastructure project in Georgia, United States, has been completed and the project is now approaching deployment readiness.
• CDT Equity Inc (NASDAQ:CDT) rose 13.3% to $2.82 in pre-market trading. CDT Equity announced that it has entered into a SAFE note with Pep’d Inc, expanding CDT’s exposure to the growing US peptide market.
• Kura Oncology Inc (NASDAQ:KURA) rose 7% to $13.25 in pre-market trading after gaining 4% on Monday.
• Navitas Semiconductor Corp (NASDAQ:NVTS) shares gained 6.7% to $13.05 in pre-market trading after the company agreed to acquire Claros for up to $232.8 million in cash and stock.

Losers

• Flash Sports & Media Holdings, Inc. (NASDAQ:FLZH) tumbled 34.4% to $0.14 in pre-market trading after dipping 77% on Monday.
• Generation Income Properties Inc (NASDAQ:GIPR) fell 34% to $0.50 in pre-market trading after jumping over 150% on Monday.
• Olenox Industries Inc (NASDAQ:OLOX) fell 20.4% to $1.63 in pre-market trading.
• Reitar Logtech Holdings Ltd (NASDAQ:RITR) declined 19.1% to $0.093 in pre-market trading. Reitar Logtech shares jumped 38% on Monday after the company announced a joint venture with Smart Pointer, advancing cold-chain fulfilment and digital supply chain services across the Greater Bay area.
• Expion360 Inc (NASDAQ:XPON) fell 19.1% to $5.02 in pre-market trading. Shares of Expion jumped around 80% on Monday, following a major strategic expansion into upstream energy.
• AIFU (NASDAQ:AIFU) fell 17.9% to $18.24 in pre-market trading after gaining 20% on Monday.
• Valion Bio Inc (NASDAQ:VBIO) fell 14.8% to $0.14 in pre-market trading after climbing over 35% on Monday. The company recently announced that Ukraine’s Ministry of Health has accepted its regulatory dossier for Entolimod for formal review under the country’s Regulatory Equivalence Pathway.
• Huadi International Group Co., Ltd. (NASDAQ:HUDI) fell 14.1% to $0.80 in pre-market trading after declining 6% on Monday.
• Aclaris Therapeutics Inc (NASDAQ:ACRS) fell 12.7% to $5.51 in pre-market trading. Aclaris Therapeutics recently posted upbeat quarterly results.
• Gorilla Technology Group Inc (NASDAQ:GRRR) fell 10.6% to $14.15 in pre-market trading following H1 results.

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.